Piper Sandler initiates Connect Biopharma stock with overweight rating

Piper Sandler initiated Connect Biopharma (CNTB) at Overweight with a $7.00 price target, implying substantial upside from $2.07, while consensus remains Strong Buy with targets ranging from $4 to $10. The key catalyst is September 2026 topline data for rademikibart in acute asthma, followed by COPD readouts, with the firm modeling about $165 million in peak risk-adjusted acute sales and $1.26 billion in chronic sales. The update reinforces the company’s first-mover potential in acute respiratory biologics and supports a favorable outlook for the stock.

Analysis

CNTB is becoming a classic binary catalyst setup where the equity can re-rate long before commercial proof exists. The market is likely underappreciating how little current value is being assigned to the acute franchise if the lead asset merely de-risks in a niche with no approved biologic competition; that creates asymmetric upside because the stock only needs credible Phase 2 efficacy and safety to unlock multiple expansion, not immediate revenue. The real value inflection is not the first readout itself, but whether the data are clean enough to attract strategic capital or a partnership ahead of the next study.

The second-order effect is that a positive signal would pressure adjacent respiratory players with earlier-stage inflammation assets, especially those dependent on chronic maintenance positioning. If acute use becomes clinically credible, it can compress the perceived time-to-market for a much larger label expansion narrative, forcing investors to reassess platform value rather than single-indication value. Conversely, if the readouts are mixed, the downside could be severe because small-cap biotech holders tend to de-risk aggressively once the market realizes the path is not just uncertain but also long-dated.

The key risk is not simply efficacy failure; it is that the asset proves safe but not differentiated enough versus standard-of-care rescue therapies, which would blunt the commercial narrative even with a statistically positive result. Timing matters: into the asthma readout window, implied volatility should rise materially, but the larger move will likely occur in the weeks after data when sell-side models update peak sales assumptions and the market decides whether the acute thesis can support follow-on financing without heavy dilution. That makes this a catalyst trade, not a fundamental compounder yet.

The contrarian angle is that consensus may be overconfident about line-of-sight from acute proof to chronic opportunity. Bridging from an exacerbation setting to maintenance is a different regulatory, payer, and prescriber problem, so the market may be embedding too much option value for a jump that still requires multiple clinical and commercial steps. If the data are merely decent, the stock could still underwhelm because investors will quickly discount the multi-year path to the larger chronic market.

Key Decisions for Investors

• Long CNTB into the September 2026 asthma readout via call spreads or a tight-risk equity position; target 2-3x upside on a clean positive signal, with defined loss if data are ambiguous.
• If already holding small-cap biotech risk, use CNTB as a hedge against acute-respiratory readthrough and consider reducing exposure to earlier-stage cytokine/respiratory names that could be pressured by a differentiated result.
• After a positive readout, buy any 1-2 day post-event pullback rather than chasing the first spike; the cleaner entry is likely after implied vol collapses and analysts reset fair value higher.
• If the stock rallies sharply into the data, consider a short-dated straddle or call spread overwrite to monetize elevated implied volatility while keeping upside participation.
• Pair idea: long CNTB / short a basket of clinically similar but less differentiated respiratory-biotech names for a 6-12 month catalyst window, with the thesis that a valid acute signal would re-rate CNTB faster than peers.